rivaroxaban / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 97 Diseases   239 Trials   239 Trials   14341 News 


«12...56789101112131415...166167»
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Praxbind (idarucizumab) / Boehringer Ingelheim
    Clinical guideline:  2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint (Pubmed Central) -  Dec 3, 2023   
    Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date, Trial primary completion date:  TRACK: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (clinicaltrials.gov) -  Nov 28, 2023   
    P3,  N=2000, Recruiting, 
    Our research highlights the discrepancy between recommendations for care and clinical practice and the need for strategy to bridge gaps in evidence-based informed decision-making. Trial completion date: Jan 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jun 2027
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Biomimetic platelet-camouflaged drug-loaded polypyrrole for the precise targeted antithrombotic therapy. (Pubmed Central) -  Nov 27, 2023   
    Trial completion date: Jan 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Jun 2027 Polypyrrole (PPy) and rivaroxban (Riv, an anticoagulant drug) were co-assembled into platelet membrane-coated nanoparticles (NPs), PLT-PPy/Riv NPs, which actively targeted the thrombotic lesion at multiple targets in the platelet membrane and were thermally and drug-specific thrombolysed by 808
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    New P1 trial:  Recanalization Rate of Acute DVT (clinicaltrials.gov) -  Nov 27, 2023   
    P1,  N=100, Not yet recruiting, 
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion date:  Rivaroxaban in Left Ventricular Thrombus (clinicaltrials.gov) -  Nov 27, 2023   
    P4,  N=320, Recruiting, 
    No abstract available Trial completion date: May 2023 --> Jan 2024
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Bevyxxa (betrixaban) / AstraZeneca
    Trial completion date, Trial primary completion date:  CORRAL-AF: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (clinicaltrials.gov) -  Nov 18, 2023   
    P=N/A,  N=2931, Not yet recruiting, 
    Dabigatran was associated with better clinical outcomes than rivaroxaban in patients with anemia or thrombocytopenia but not in those with anemia and thrombocytopenia. Trial completion date: Aug 2033 --> Dec 2033 | Trial primary completion date: Aug 2028 --> Dec 2028
  • ||||||||||  Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
    Trial initiation date:  THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=6660, Not yet recruiting, 
    However, this still needs validation by further studies particularly among patients with morbid obesity. Initiation date: Oct 2023 --> Jan 2024
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
    Journal:  Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity. (Pubmed Central) -  Nov 17, 2023   
    Limitations of this study include the retrospective single-center study design. There was a comparable risk of bleeding and recurrent VTE between DOACs and warfarin in patients initiated on therapy for VTE.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal, Surgery:  Bleeding and thromboembolic risk in patients under anticoagulant therapy receiving oral surgery: a systematic review. (Pubmed Central) -  Nov 16, 2023   
    The results of both treatment categories (continuous versus discontinuous anticoagulant and continuous versus interruption and switch to bridging therapy) showed no significant differences in terms of bleeding events. However, the use of scores that assess the risk of thrombosis and bleeding can assist surgeons in anticipating the degree of postoperative complications and making informed treatment decisions.
  • ||||||||||  rivaroxaban / Generic mfg.
    Management of Femoral and Ilioinguinal Neuropathy Due to Iliacus Hematoma in Patient on Chronic Anticoagulation: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_470;    
    Case Diagnosis: 77 year old male with history of atrial fibrillation on chronic Rivaroxaban develops femoral and ilioinguinal neuropathy secondary to right iliacus hematoma.Case Description or Program Description: The patient presented with sudden-onset right-sided hip pain upon repositioning himself at home... Prompt identification and drainage of Iliacus hematoma must be considered in a patient presenting with abrupt-onset hip pain on chronic anticoagulation in efforts to preserve nerve function.
  • ||||||||||  Review, Journal:  Potentially active compounds that improve PAD through angiogenesis: A review. (Pubmed Central) -  Nov 15, 2023   
    This paper focuses on the therapeutic effect of natural products (Salidroside, Astragaloside IV, etc.) and synthetic compounds (Cilostazol, Dapagliflozin, etc.)...Overall, these exogenous compounds have promising therapeutic potential for PAD. This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.
  • ||||||||||  rivaroxaban / Generic mfg., amiodarone / Generic mfg.
    Journal:  Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation. (Pubmed Central) -  Nov 14, 2023   
    The combination of rivaroxaban and amiodarone increased the risk of bleeding in patients with atrial fibrillation, especially clinically relevant nonmajor and minor bleeding. Physicians prescribing rivaroxaban and amiodarone together should be concerned about an increase in the risk of nonmajor bleeding.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Journal:  Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey. (Pubmed Central) -  Nov 13, 2023   
    Furthermore, prescribers who were more confident in DOAC prescribing, and were more worried about the risk of stroke, were significantly less likely to inappropriately underdose. These findings suggest that all prescribers, regardless of speciality, may benefit from education and training to raise awareness of the risks associated with inappropriate DOAC underdosing.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Extensive arm skin necrosis following administration of unfractionated heparin. (Pubmed Central) -  Nov 10, 2023   
    The patient was discharged in good condition after completing treatment for CIDP without any need for surgical removal of the necrotic tissue. Extensive skin necrosis, as a result of HIT, requires immediate discontinuation of UH and substitution of a nonheparin-based anticoagulation treatment.
  • ||||||||||  rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
    Journal:  Thromboembolic complications during and after embolization of unruptured aneurysms: A chronological outcome in periprocedural thromboembolic events. (Pubmed Central) -  Nov 9, 2023   
    Thromboembolic events developed at a certain rate; thus, rivaroxaban was administered with single-antiplatelet therapy (SAPT) to improve thromboembolic results (Phase 2), showing better outcomes than in Phase 1...Ischemic complications were evaluated in each phase or compared between the DAPT group and the direct oral anticoagulant (DOAC) with the clopidogrel (DOAC+SAPT) group...Therefore, accumulated experience or a learning curve could not explain the results. DOAC administration might decrease the risk of these events, but further accumulation of evidence or prospective investigation is warranted.
  • ||||||||||  rivaroxaban / Generic mfg.
    Enrollment open, Trial initiation date:  Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty (clinicaltrials.gov) -  Nov 8, 2023   
    P=N/A,  N=120, Recruiting, 
    DOAC administration might decrease the risk of these events, but further accumulation of evidence or prospective investigation is warranted. Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> May 2022
  • ||||||||||  rivaroxaban / Generic mfg.
    Review, Journal:  Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation. (Pubmed Central) -  Nov 7, 2023   
    Moreover, in the AF population, additional to its ability to reduce the risk of thromboembolic complications, rivaroxaban is associated with a lower risk of myocardial infarction, major adverse cardiac and limb events, and vascular mortality in patients with diabetes, also attenuating renal impairment during follow-up. These findings suggest that rivaroxaban may provide a comprehensive vascular protection in patients with AF.